GMAB Short Volume
Genmab A/S (GMAB) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $22.45B, listed on NASDAQ, employing roughly 3,119 people, carrying a beta of 0.65 to the broader market. Genmab A/S, a biopharmaceutical company founded in 1999 and headquartered in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody therapies primarily for treating cancer and various other serious illnesses. Led by Jan van de Winkel, public since 2009-06-01.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-10-14
- Short Volume
- 535.9K
- Total Volume
- 805.1K
- Short %
- 66.57%
- 30-Day Avg Short %
- 58.36%
Showing 30 days of FINRA short volume data for Genmab A/S.
Learn how short volume is reported and how to read the data →
Frequently asked GMAB short volume questions
- What is the daily GMAB short volume?
- As of Oct 14, 2026, Genmab A/S (GMAB) short volume is 535.9K shares against 805.1K total reported volume, or 66.57% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is GMAB short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does GMAB short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.